Sahil Banwala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sahil Banwala has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ajay Kumar
Sharda University
1 shared publication Asif Husain
Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and Research (SPER), Jamia Hamdard, New Delhi 110062, India
1 shared publication- Karan Wadhwa
Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak, 124001, India
1 shared publication - Rakesh Kumar Sindhu
School of Pharmacy, Sharda University, Gr Noida
1 shared publication - Shuchi Goyal
Chitkara College of Pharmacy, Chitkara University, Punjab, India
1 shared publication Simranjeet Kaur
Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra 136119, India
1 shared publication
Latest Publications
- Open Access
- 6 June 2025
- Published by The ScienceIn Publishing in Journal of Integrated Science and Technology
- Vol. 13 (7) , 1152
Proniosome-based smart delivery systems for Psoriasis-targeted bioactive therapy
The growth in the field of nanotechnology has brought forth the growth of several breakthroughs that have prompted formulation of new solutions. Nanocarriers occur as minute encapsulating agents of the drug molecules thus stabilizing and improving the therapeutic effects of the encapsulated drugs. The self-assembly characteristic of proniosomes reduces the challenges that are normally encountered in liposomal and niosomal drug delivery systems. Due to their ability to self-assemble, proniosomes are the focus of constant investigating in the field of drug delivery systems. However, there is still great potential for future research concerning the development of new carrier materials for proniosomal formulation. Versatile proniosome-derived niosomes prove to be a reliable and relatively inexpensive system for drug delivery that possesses a number of significant advantages over conventional vesicular and traditional pharmaceutical formulations. Bioactive agents and recent advancements along with ethical considerations in the formation of proniosomes for psoriasis is further discussed in this review article. Novel hypotheses estimate repeated improvements in oral biopharmacokinetics, preferential drug targeting to the site of action, postponing the systemic biotransformation of the drug, which would lead to minimizing toxicity.
- 6 June 2025
- Published by The ScienceIn Publishing in Journal of Integrated Science and Technology
- Vol. 13 (7) , 1152
Open AccessProniosome-based smart delivery systems for Psoriasis-targeted bioactive therapy
The growth in the field of nanotechnology has brought forth the growth of several breakthroughs that have prompted formulation of new solutions. Nanocarriers occur as minute encapsulating agents of the drug molecules thus stabilizing and improving the therapeutic effects of the encapsulated drugs. The self-assembly characteristic of proniosomes reduces the challenges that are normally encountered in liposomal and niosomal drug delivery systems. Due to their ability to self-assemble, proniosomes are the focus of constant investigating in the field of drug delivery systems. However, there is still great potential for future research concerning the development of new carrier materials for proniosomal formulation. Versatile proniosome-derived niosomes prove to be a reliable and relatively inexpensive system for drug delivery that possesses a number of significant advantages over conventional vesicular and traditional pharmaceutical formulations. Bioactive agents and recent advancements along with ethical considerations in the formation of proniosomes for psoriasis is further discussed in this review article. Novel hypotheses estimate repeated improvements in oral biopharmacokinetics, preferential drug targeting to the site of action, postponing the systemic biotransformation of the drug, which would lead to minimizing toxicity.
- 1 August 2021
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 21 (2) , 130-141
Synthesis, Molecular Docking, and Biological Evaluation of Some Novel 2-(5-Substituted 1,3,4-oxadiazole-2-yl)-1,3-benzothiazole Derivatives as Anticonvulsant Agents
Background: Benzothiazole is an organosulfur heterocyclic compound that has a considerable place in drug discovery due to significant pharmacological actions. Objective: The main objective of the present study was to synthesize some novel 2-(5-substituted 1,3,4-oxadiazole-2-yl)-1,3-benzothiazole derivatives and evaluate them for their anticonvulsant activity using in silico and in vivo methods. Methods: A set of sixteen 2-(5-substituted 1, 3, 4-oxadiazole-2-yl)-1, 3-benzothiazole derivatives were prepared using multi-step reactions starting from o-amino-thiophenol and characterized by suitable spectral techniques. The synthesized compounds were evaluated for anticonvulsant activity using in silico and in vivo methods. In silico molecular docking study was performed using Molegro Virtual Docker software to analyze binding modes of compounds with the internal ligand of PDB ID: 1OHY and 1OHV; and in vivo pharmacological activities were tested for both generalized tonic-clonic seizures and generalized absence (petit mal) seizures using Maximal Electrical Shock and PTZ-induced seizure models, respectively. Results: Some new 2-(5-substituted-1,3,4-oxadiazole-2-yl)-1,3- benzothiazole (5a-5p) were successfully synthesized by finally refluxing 1, 3-benzothiazole-2-carboxyhydrazide with different aromatic acids in phosphoryl chloride. Docking results showed that compounds 5c, 5j, and 5m were found to have the highest number of H-bond interactions; i.e. 4, 4, and 7 respectively with target proteins 1OHY and 6, 3, and 4 respectively with target protein 1OHV, whereas phenytoin showed only two H-bonding with both proteins. In the Maximal electroshock seizure method, the synthesized compounds 5h, 5k and 5o demonstrated potent anticonvulsant activity against the tonic seizure with a significant decrease in tonic hind leg extension period with a mean duration of 7.9, 7.4, and 7.0 sec respectively, as compared to the other synthesized compounds. In contrast, in the PTZ-induced seizure model, compounds 5c, 5h, and 5m showed protection against clonic convulsion with significant elevation in the onset time of clonic convulsion at 311.2, 308.0, and 333.11 sec, respectively. Conclusion: Thus, from the results, it can be concluded that compound 5h, a benzothiazole derivative endowed with an oxadiazole ring, can be developed as a potential anticonvulsant agent.
- 1 August 2021
- Published by Bentham Science Publishers Ltd. in Central Nervous System Agents in Medicinal Chemistry
- Vol. 21 (2) , 130-141
Synthesis, Molecular Docking, and Biological Evaluation of Some Novel 2-(5-Substituted 1,3,4-oxadiazole-2-yl)-1,3-benzothiazole Derivatives as Anticonvulsant Agents
Background: Benzothiazole is an organosulfur heterocyclic compound that has a considerable place in drug discovery due to significant pharmacological actions. Objective: The main objective of the present study was to synthesize some novel 2-(5-substituted 1,3,4-oxadiazole-2-yl)-1,3-benzothiazole derivatives and evaluate them for their anticonvulsant activity using in silico and in vivo methods. Methods: A set of sixteen 2-(5-substituted 1, 3, 4-oxadiazole-2-yl)-1, 3-benzothiazole derivatives were prepared using multi-step reactions starting from o-amino-thiophenol and characterized by suitable spectral techniques. The synthesized compounds were evaluated for anticonvulsant activity using in silico and in vivo methods. In silico molecular docking study was performed using Molegro Virtual Docker software to analyze binding modes of compounds with the internal ligand of PDB ID: 1OHY and 1OHV; and in vivo pharmacological activities were tested for both generalized tonic-clonic seizures and generalized absence (petit mal) seizures using Maximal Electrical Shock and PTZ-induced seizure models, respectively. Results: Some new 2-(5-substituted-1,3,4-oxadiazole-2-yl)-1,3- benzothiazole (5a-5p) were successfully synthesized by finally refluxing 1, 3-benzothiazole-2-carboxyhydrazide with different aromatic acids in phosphoryl chloride. Docking results showed that compounds 5c, 5j, and 5m were found to have the highest number of H-bond interactions; i.e. 4, 4, and 7 respectively with target proteins 1OHY and 6, 3, and 4 respectively with target protein 1OHV, whereas phenytoin showed only two H-bonding with both proteins. In the Maximal electroshock seizure method, the synthesized compounds 5h, 5k and 5o demonstrated potent anticonvulsant activity against the tonic seizure with a significant decrease in tonic hind leg extension period with a mean duration of 7.9, 7.4, and 7.0 sec respectively, as compared to the other synthesized compounds. In contrast, in the PTZ-induced seizure model, compounds 5c, 5h, and 5m showed protection against clonic convulsion with significant elevation in the onset time of clonic convulsion at 311.2, 308.0, and 333.11 sec, respectively. Conclusion: Thus, from the results, it can be concluded that compound 5h, a benzothiazole derivative endowed with an oxadiazole ring, can be developed as a potential anticonvulsant agent.